

**Northwestern University Institutional Biosafety Committee  
Meeting Minutes**

Date: 02/18/2026 11:00 AM

Called to Order:

Adjourned:

Location: 345 E Superior St, Suite 1522, Chicago, IL 60611

Northwestern University conducts some or all of its IBC meetings via teleconference. A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

**IBC Members**

<b>Name</b>	<b>Committee Role</b>	<b>Attendance</b>
Mary Hummel	Chair	Present
Greg Smith	Chair	Present
Gregory Beitel	Member	Present
Jennifer Brace	Member	Present
Jacob Class	Member	Present
Alexis Demonbreun	Member	Present
Adriana Ferreira	Member	Present
Robert Foreman	Member	Present
Susan Fox	Member	Absent
Lucy Godley	Member	Absent
Erica Hartmann	Member	Present
Sydni Hill	Member	Present
Robert Holmgren	Member	Present
Changhwa Hwang	Member	Present
Sarah Kopp	Member	Present
Maciej Lesniak	Member	Absent
Stephen Levin	Member	Present
Liming Li	Member	Absent
Michael McRaven	Member	Present
Jeremy T Ritzert	Member	Present
Irina Shepotinovskaya	Member	Absent
Suchitra Swaminathan	Member	Present
Clyde Yancy	Member	Absent
Nicolette Zielinski-Mozny	Member	Present
Raza Akbar	Alternate	Absent
Robert Birkett	Alternate	Present
Mandy Kozlowski	Alternate	Present
Alicia McLuckie	Alternate	Absent
Marina Zelivyanskaya	Alternate	Absent

<b>Name</b>	<b>Committee Role</b>	<b>Attendance</b>
James Zewe	Alternate	Present
Robert Foreman	Administrator	Present
Michael Hantak	Administrator	Present
Sarah Kopp	Administrator	Present
Iwona Spath	Administrator	Present

### **Registrations for Full-Committee Review**

Research Group	Principal Investigator	Submission Type
Amendment for BIO20220041	Guillermo Ameer	Amendment
Amendment/CR for BIO20240057	Elizabeth Eklund	Amendment/CR
Galiano Lab	Robert Galiano	Initial Protocol
Kozorovitskiy Lab	Yevgenia Kozorovitskiy	Initial Protocol
Bio-Science - Teaching Lab	John Mordacq	Initial Protocol
Amendment for BIO20220014	Murali Prakriya	Amendment
Quaggin Lab	Susan Quaggin	Initial Protocol
Amendment/CR for BIO20230045	Greg Smith	Amendment/CR
Amendment for BIO20220113	Adam Williams	Amendment

### **Approval of Previous Meeting Minutes**

Previous Meeting Date: 1/21/26 11:30 AM

Determination: Approve

Comments: A Committee Member made a motion to approve the meeting minutes. The Committee unanimously supported the motion.

## Meeting Minutes

### Review of Amendment for BIO20220041

Amendment

**Principal Investigator:** Guillermo Ameer

**Submission ID:** BIO20220041-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-b
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Defer

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to defer this submission.

The Committee unanimously supported the motion.

## **Review of Amendment/CR for BIO20240057**

Amendment/CR

**Principal Investigator:** Elizabeth Eklund

**Submission ID:** BIO20240057-AMCR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F-1
- Section III-D-1
- Section III-D-3
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved with minor modifications

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

## Review of Galiano Lab

Initial Protocol

**Principal Investigator:** Robert Galiano

**Submission ID:** BIO20260001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-E-3
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D
- Section III-D-3-a

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved with minor modifications

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

## Review of Kozorovitskiy Lab

Initial Protocol

**Principal Investigator:** Yevgenia Kozorovitskiy

**Submission ID:** BIO20250117

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## Review of Bio-Science - Teaching Lab

Initial Protocol

**Principal Investigator:** John Mordacq

**Submission ID:** BIO20250112

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20220014**

Amendment

**Principal Investigator:** Murali Prakriya

**Submission ID:** BIO20220014-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## Review of Quaggin Lab

Initial Protocol

**Principal Investigator:** Susan Quaggin

**Submission ID:** BIO20260006

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## Review of Amendment/CR for BIO20230045

Amendment/CR

**Principal Investigator:** Greg Smith

**Submission ID:** BIO20230045-AMCR0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-F-2
- Section III-F
- Section III-D-2-a
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved with minor modifications

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

## Review of Amendment for BIO20220113

### Amendment

**Principal Investigator:** Adam Williams

**Submission ID:** BIO20220113-AM0003

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-7
- Section III-D-4-b
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Administratively-Approved Exempt Registrations and Amendments**

### **Amendment for BIO20250046**

Amendment

**Principal Investigator:** Daniel Batlle

**Submission ID:** BIO20250046-AM0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-F-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8-C-VIII

**Containment Level:** BSL-2

**Approval Date:** 2/2/2026

### **Continuing Review for BIO20220047**

Continuing Review

**Principal Investigator:** Issam Ben-Sahra

**Submission ID:** BIO20220047-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/11/2026

## **Continuing Review for BIO20240129**

Continuing Review

**Principal Investigator:** Shayna Bradford

**Submission ID:** BIO20240129-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8-C-VII
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/22/2026

## **Continuing Review for BIO20250019**

Continuing Review

**Principal Investigator:** Mary Cheatham

**Submission ID:** BIO20250019-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-8-C-VII

**Containment Level:** BSL-1

**Approval Date:** 2/18/2026

## **Continuing Review for BIO20220073**

Continuing Review

**Principal Investigator:** Weiguo Cui

**Submission ID:** BIO20220073-CR0002

### **Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-D-7
- Section III-D-4-b
- Section III-D-4
- Section III-F
- Section III-D-2-a
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/5/2026

## **Amendment for BIO20220034**

Amendment

**Principal Investigator:** Lillian Eichner

**Submission ID:** BIO20220034-AM0002

### **Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/28/2026

## **El Tecle Lab**

Initial Protocol

**Principal Investigator:** Najib El Tecle

**Submission ID:** BIO20250122

**Applicable NIH Guidelines:**

**Containment Level:** BSL-1

**Approval Date:** 1/20/2026

## **Continuing Review for BIO20240091**

Continuing Review

**Principal Investigator:** Andrew Fink

**Submission ID:** BIO20240091-CR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-D-4
- Section III-F-1
- Section III-D-1
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/30/2026

## **Continuing Review for BIO20240173**

Continuing Review

**Principal Investigator:** Marco Gallio

**Submission ID:** BIO20240173-CR0001

**Applicable NIH Guidelines:**

- Section III-F-3
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/6/2026

## **Gefen Lab**

Initial Protocol

**Principal Investigator:** Tamar Devora Gefen

**Submission ID:** BIO20250118

**Applicable NIH Guidelines:**

**Containment Level:** BSL-1

**Approval Date:** 2/9/2026

## **Amendment/CR for BIO20220017**

Amendment/CR

**Principal Investigator:** Nayereh Ghoreishi

**Submission ID:** BIO20220017-AMCR0002

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/11/2026

## **Amendment for BIO20230063**

Amendment

**Principal Investigator:** Lucy Godley

**Submission ID:** BIO20230063-AM0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/16/2026

## **Continuing Review for BIO20230013**

Continuing Review

**Principal Investigator:** Eric Hungness

**Submission ID:** BIO20230013-CR0002

Applicable NIH Guidelines:

**Containment Level:** BSL-2

**Approval Date:** 1/26/2026

## **Amendment for BIO20220147**

Amendment

**Principal Investigator:** Shana Kelley

**Submission ID:** BIO20220147-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-4-c
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/2/2026

## **Amendment for BIO20220042**

Amendment

**Principal Investigator:** John Kessler

**Submission ID:** BIO20220042-AM0004

### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/23/2026

## **Amendment for BIO20230076**

Amendment

**Principal Investigator:** Irum Khan

**Submission ID:** BIO20230076-AM0001

### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-b
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/2/2026

## **Continuing Review for BIO20230022**

Continuing Review

**Principal Investigator:** Joshua Leonard

**Submission ID:** BIO20230022-CR0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-F-2
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-3

**Containment Level:** BSL-2

**Approval Date:** 2/13/2026

## **Amendment for BIO20250025**

Amendment

**Principal Investigator:** Maciej Lesniak

**Submission ID:** BIO20250025-AM0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-4-c
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/16/2026

## **Continuing Review for BIO20220133**

Continuing Review

**Principal Investigator:** Hao Li

**Submission ID:** BIO20220133-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/21/2026

## **Amendment for BIO20220152**

Amendment

**Principal Investigator:** Xiao-Nan Li

**Submission ID:** BIO20220152-AM0001

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3

**Containment Level:** BSL-2

**Approval Date:** 2/11/2026

## **Continuing Review for BIO20220152**

Continuing Review

**Principal Investigator:** Xiao-Nan Li

**Submission ID:** BIO20220152-CR0002

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3

**Containment Level:** BSL-2

**Approval Date:** 1/29/2026

## **Continuing Review for BIO20240187**

Continuing Review

**Principal Investigator:** Richard Longnecker

**Submission ID:** BIO20240187-CR0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-F-2
- Section III-E-3
- Section III-F-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 12/11/2025

## **Continuing Review for BIO20220155**

Continuing Review

**Principal Investigator:** Molly Losh

**Submission ID:** BIO20220155-CR0002

**Applicable NIH Guidelines:**

**Containment Level:** BSL-1

**Approval Date:** 1/9/2026

## **Amendment for BIO20220015**

### Amendment

**Principal Investigator:** Stephen Miller

**Submission ID:** BIO20220015-AM0005

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/23/2026

## **Continuing Review for BIO20250030**

### Continuing Review

**Principal Investigator:** Alexander Misharin

**Submission ID:** BIO20250030-CR0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-3

**Approval Date:** 1/29/2026

## **Continuing Review for BIO20250065**

### Continuing Review

**Principal Investigator:** Brian Mitchell

**Submission ID:** BIO20250065-CR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-F-3
- Section III-F-8-C-I
- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D

**Containment Level:** BSL-2

**Approval Date:** 1/29/2026

### **Amendment for BIO20240043**

#### Amendment

**Principal Investigator:** Luisa Morales-Nebreda

**Submission ID:** BIO20240043-AM0008

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-7
- Section III-D-4
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 2/3/2026

### **Continuing Review for BIO20230004**

#### Continuing Review

**Principal Investigator:** Samdeep Mouli

**Submission ID:** BIO20230004-CR0001

**Applicable NIH Guidelines:**

- Section III-E

**Containment Level:** BSL-1

**Approval Date:** 5/5/2025

### **Amendment for BIO20250060**

#### Amendment

**Principal Investigator:** Guillermo Oliver

**Submission ID:** BIO20250060-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-b
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/27/2026

## **Continuing Review for BIO20250060**

Continuing Review

**Principal Investigator:** Guillermo Oliver

**Submission ID:** BIO20250060-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-b
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/21/2026

## **Continuing Review for BIO20220027**

Continuing Review

**Principal Investigator:** Egon Ozer

**Submission ID:** BIO20220027-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1

**Containment Level:** BSL-2+

**Approval Date:** 2/5/2026

### **Continuing Review for BIO20220154**

Continuing Review

**Principal Investigator:** Amy Paller

**Submission ID:** BIO20220154-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/17/2026

### **Amendment for BIO20230011**

Amendment

**Principal Investigator:** Joo-Seop Park

**Submission ID:** BIO20230011-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-1

**Approval Date:** 1/24/2026

### **Continuing Review for BIO20220099**

Continuing Review

**Principal Investigator:** Harris Perlman

**Submission ID:** BIO20220099-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 1/15/2026

## **Continuing Review for BIO20240172**

Continuing Review

**Principal Investigator:** Marcus Peter

**Submission ID:** BIO20240172-CR0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-F-2
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-F
- Section III-D-2-a
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/17/2026

## **Continuing Review for BIO20220106**

Continuing Review

**Principal Investigator:** Daniele Procissi

**Submission ID:** BIO20220106-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** N/A

**Approval Date:** 1/6/2026

## **Amendment for BIO20220026**

### Amendment

**Principal Investigator:** Wenan Qiang

**Submission ID:** BIO20220026-AM0002

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-D-4-b
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-D-1
- Section III-D
- Section III-D-4-c
- Section III-D-3

**Containment Level:** BSL-2

**Approval Date:** 1/20/2026

## **Continuing Review for BIO20220116**

### Continuing Review

**Principal Investigator:** Jeffrey Rado

**Submission ID:** BIO20220116-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-2

**Approval Date:** 1/22/2026

## **Continuing Review for BIO20220045**

### Continuing Review

**Principal Investigator:** Luis Rosas-Vidal

**Submission ID:** BIO20220045-CR0002

**Applicable NIH Guidelines:**

**Containment Level:** BSL-2

**Approval Date:** 2/16/2026

### **Amendment/CR for BIO20230015**

Amendment/CR

**Principal Investigator:** Adam Sonabend Worthalter

**Submission ID:** BIO20230015-AMCR0002

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/6/2026

### **Continuing Review for BIO20240153**

Continuing Review

**Principal Investigator:** Farzaneh Sorond

**Submission ID:** BIO20240153-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-2

**Approval Date:** 2/2/2026

### **Amendment for BIO20240184**

Amendment

**Principal Investigator:** Beatriz Sosa-Pineda

**Submission ID:** BIO20240184-AM0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-F-8-C-I
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-8-C-VII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/27/2026

### **Continuing Review for BIO20250069**

Continuing Review

**Principal Investigator:** Peter Sporn

**Submission ID:** BIO20250069-CR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-E
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/28/2026

### **Continuing Review for BIO20230130**

Continuing Review

**Principal Investigator:** Stuart Stock

**Submission ID:** BIO20230130-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-1

**Approval Date:** 2/9/2026

### **Continuing Review for BIO20220022**

Continuing Review

**Principal Investigator:** Samuel Stupp

**Submission ID:** BIO20220022-CR0002

**Applicable NIH Guidelines:**

**Containment Level:** BSL-1

**Approval Date:** 2/16/2026

### **Continuing Review for BIO20230064**

Continuing Review

**Principal Investigator:** Geoffrey Swanson

**Submission ID:** BIO20230064-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/22/2026

## **Amendment for BIO20240127**

### Amendment

**Principal Investigator:** Jacob Sznajder

**Submission ID:** BIO20240127-AM0001

#### **Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-D-7
- Section III-F-3
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 1/21/2026

## **Continuing Review for BIO20250001**

### Continuing Review

**Principal Investigator:** Colby Thaxton

**Submission ID:** BIO20250001-CR0001

#### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/18/2026

## **Continuing Review for BIO20240145**

### Continuing Review

**Principal Investigator:** Robert Vassar

**Submission ID:** BIO20240145-CR0001

#### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-E
- Section III-F-8-C-VII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/29/2026

### **Continuing Review for BIO20230033**

Continuing Review

**Principal Investigator:** Xiaozhong Wang

**Submission ID:** BIO20230033-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/4/2026

### **Continuing Review for BIO20230038**

Continuing Review

**Principal Investigator:** Bin Zhang

**Submission ID:** BIO20230038-CR0002

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/22/2026

### **Continuing Review for BIO20230047**

Continuing Review

**Principal Investigator:** Jing Zheng

**Submission ID:** BIO20230047-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-E
- Section III-F-1
- Section III-F-8-C-VII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 2/4/2026

## **Continuing Review for BIO20220092**

Continuing Review

**Principal Investigator:** Yongling Zhu

**Submission ID:** BIO20220092-CR0002

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-4-c
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 1/26/2026

## **Continuing Review for BIO20230081**

Continuing Review

**Principal Investigator:** Joshua Ziarek

**Submission ID:** BIO20230081-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-1

**Approval Date:** 2/6/2026

## Other Agenda Items